Table 1.
Aβ Immunotherapies in development.
| Drug Name | Sponsor | Characteristics | Phase | References | |
|---|---|---|---|---|---|
| Monoclonal Antibodies | Epitope* | Isotype | |||
| Bapineuzumab (AAB-001) | Janssen/Elan/Pfizer | 1–5 (free N- terminus) | IgG1 | III | [1,53]; NCT00575055 and NCT00574132 |
| Solanezumab (LY2062430) | Eli Lilly | 13–28 | IgG1 | III | [37–40]; NCT00905372 |
| PF-04360365 | Pfizer | 33–40 (free C- terminus) | IgG2 | II | [42,62]; NCT00722046 |
| MABT5102A | Genentech | NP | NP | I | [43,63]; NCT00736775 |
| GSK933776A | GlaxoSmithKline | NP | NP | I | NCT00459550 |
| Gantenerumab (R1450/RO4909832) | Hoffmann-La Roche | NP | IgG1 | I | NCT00531804 |
| Intravenous Immunoglobulin | |||||
| Gammagard | Baxter; NIH Alzheimer’s Disease Cooperative Study | III | [46]; NCT00818662 | ||
| Octagam | Octapharma | II | NCT00812565 | ||
| Active Vaccines | Fragment* | ||||
| CAD106 | Novartis | 1–6 | II | [64]; NCT00795418 | |
| ACC001 | Pfizer | 1–7 | II | NCT00498602 | |
| UB311 | United Biochemical | 1–14 | I | NCT00965588 | |
| V950 | Merck | NP | I | NCT00464334 | |
| AD01/AD02 | Affiris | ** | I | [47]; NCT00711139/NCT00711321 | |
NP, not published
*
Numbers correspond to amino acid positions on the Aβ peptide
**
6-amino acid peptides that mimic the free N-terminus of Aβ [47]